Home Tools

c-RET

RET is the receptor for GDNF-family ligands (GFLs).

Cat. No.	Product name	CAS No.	Purity
T16995	TAS05567	1429038-15-2	98%
T16995	TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
T10823	Trans-Pralsetinib	2097132-93-7	98%
T10823	trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).
T14928	Agerafenib hydrochloride	1227678-26-3	98%
T14928	Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
T1995	Fedratinib	936091-26-8	99.96%
T1995	Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
T12598	Pz-1	1800505-64-9	99.95%
T12598	Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
T4301	AD80	1384071-99-1	99.9%
T4301	AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
T2586	Cabozantinib	849217-68-1	99.88%
T2586	Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Caboz...
T1792	Regorafenib	755037-03-7	99.87%
T1792	Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active...
T67779	Compound TPX-0046	2411115-73-4	99.85%
T67779	Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
T0520	Lenvatinib	417716-92-8	99.8000%
T0520	Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib h...
T5491	GSK3179106	1627856-64-7	99.8%
T5491	GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM
T62285	Enbezotinib	2359649-81-1	99.79%
T62285	Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
T8222	Selpercatinib	2152628-33-4	99.77%
T8222	Selpercatinib (LOXO-292) is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET...
T8467	RET V804M-IN-1	2414909-94-5	99.62%
T8467	RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
T6920	ON123300	1357470-29-1	99.53%
T6920	ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T9673	RET-IN-3	2414374-53-9	99.52%
T9673	RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.
T1792L	Regorafenib monohydrate	1019206-88-2	99.47%
T1792L	Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR...
T2070	Agerafenib	1188910-76-0	99.23%
T2070	Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.
T8541	Lenvatinib mesylate	857890-39-2	99.03%
T8541	Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
T3065	TG101209	936091-14-4	99%
T3065	TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.